Tumor cells utilize glutamine as a fuel source for the tricarboxylic acid (TCA) cycle, and targeting intermediates of the TCA cycle involved in glutaminolysis has proven to be an effective anticancer approach.362 New specific glutaminase (GLS) inhibitors, including CB-839 selenadiazole-derivatives CPD-20 and CPD-23, have been observed to demonstrate enhanced uptake in tumor cells and exhibit higher anticancer activity against CRC cells. The gene discussed is GLS; the disease is colorectal carcinoma.